Pfizer Wins Lipitor Patent Case Against Ranbaxy
Posted on: Wednesday, 11 July 2007, 12:04 CDT
Pfizer said that the Irish High Court has ruled that the basic patent covering atorvastatin - the active ingredient in the company's Lipitor cholesterol drug - would be infringed by a rival product from generics manufacturer Ranbaxy.
The decision, which is subject to a possible appeal, prevents Ranbaxy from launching its drug before the basic Lipitor patent expires in November 2011.
"Today's decision is yet another affirmation of the strength of the intellectual property behind Lipitor," said Pfizer general counsel Allen Waxman.
Source: Datamonitor
Related Articles
- Kansas City grand jury indicts 11 in Lipitor scam
- Pfizer Posts Q2 Profit on Lipitor Sales
- New Data Analysis Shows Patients With Diabetes Taking Pfizer's Lipitor(R) Experienced Major Reductions in Heart Attack and Stroke
- Lipitor, Celecoxib Combo Limits Cancer
- Pfizer Touts New Lipitor Study
- Study Showed VYTORIN-TM- -Ezetimibe/Simvastatin- Superior to Lipitor at Lowering LDL -Bad- Cholesterol
- Lipitor Patients Who Reduced 'Bad' Cholesterol To Very Low Levels Show Significant Decrease in Heart Attack and Stroke, New Data Show
- New Trial Showed VYTORIN-TM- -Ezetimibe/Simvastatin- Superior Again to Lipitor at Lowering LDL -Bad- Cholesterol
- Health Officials Warn of Fake Lipitor
- FDA Recalls Lipitor Due to Fake Pills
Rating: 2.9 / 5 (15 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds